Table 1.
Baseline characteristics of the included trials.
| Study, Year | Location; Time Period | Neoplasia | Intervention (N) | Control (N) | Max Diameter Common Bile Duct (mm) | Age | Gender, Male | Definition of Clinical Success |
|---|---|---|---|---|---|---|---|---|
| EUS-choledochoduodenostomy vs. PTBD | ||||||||
| Artifon, 2012 [18] | Brazil; 2007–2011 | Pancreatic adenocarcinoma 16, Ampullary adenocarcinoma 1, Hematologic neoplasia 2, Cholangiocarcinoma 2, Metastasis 3, Gastric carcinoma 1. |
EUS-CD with SEMS (13) | PTBD with SEMS (12) | EUS-CD 13.7 (9 to 28) PTBD 11.9 (8 to 23) |
EUS-CD 63.4 ± 11.1 PTBD 71 ± 11.9 |
EUS-CD 9 (69.2%) PTBD 8 (66.6%) |
Improvement of clinical symptoms and decrease in liver enzymes |
| Lee, 2016 (I) [19] * | Korea; 2014–2015 | Cholangiocarcinoma 21, Pancreatic adenocarcinoma 24, Gallbladder carcinoma 8, Ampullary adenocarcinoma 1, Metastasis 4, Gastric carcinoma cancer 5, Duodenal carcinoma 3 |
EUS-CD with SEMS (8) | PTBD with SEMS (32) | EUS-CD 11.2 ± 4.38 PTBD 12.6 ± 6.18 |
EUS-CD 66.5 (40–83) PTBD 68.4 (52–82) |
EUS-CD NR PTBD 24 (75%) |
Decrease in bilirubin level to less than 50% of baseline within 7 days, or less than 75% within 30 days. |
| EUS-choledochoduodenostomy vs. Surgical hepaticojejunostomy | ||||||||
| Artifon, 2015 [20] | Brazil; 2011–2013 | NR | EUS-CD with SEMS (16) | Surgical hepaticojejunostomy (16) | EUS-CD 20 Hepaticojejunostomy 20 | EUS-CD 65 ± 12.2 Hepaticojejunostomy 68.1 ± 19.5 |
EUS-CD 7 (43.7%) Hepaticojejunostomy 7 (43.7%) |
Decrease in bilirubin level to less than 50% of baseline within 7 days |
| EUS-choledochoduodenostomy vs. EUS-hepaticogastrostomy | ||||||||
| Minaga, 2019 [10] | Japan; 2013–2016 | Pancreatobiliary cancer 41, Other 6 |
EUS-CD with SEMS (23) | EUS-HG with SEMS (24) | NR | EUS-CD 73 (41–83) EUS-HG 72.5 (46–88) |
EUS-CD 10 (43.4%) EUS-HG 14 (58.3%) |
Decrease in bilirubin level to less than 50% of baseline within 14 days |
| Artifon, 2015 [21] | Brazil; 2010–2013 | Pancreatic adenocarcinoma 33, Metastatic adenopathy 8, Ampullary carcinoma 4, Neuroendocrine tumor 2, Gallbladder cancer 1, Duodenal carcinoma 1 |
EUS-CD with SEMS (24) | EUS-HG with SEMS (25) | EUS-CD 22.23 ± 4.09 EUS-HG 21.43 ± 4.88 |
EUS-CD 65.7 (15–74) EUS-HG 66.25 (14–28) |
EUS-CD 11 (45.8%) EUS-HG 11 (44%) |
Decrease in bilirubin level to less than 50% of baseline within 7 days |
| EUS-hepaticogastrostomy vs. PTBD | ||||||||
| Lee, 2016 (II) [19] * | Korea; 2014–2015 | Cholangiocarcinoma 21, Pancreatic adenocarcinoma 24, Gallbladder carcinoma 8, Ampullary adenocarcinoma 1, Metastasis 4, Gastric carcinoma cancer 5, Duodenal carcinoma 3 |
EUS-HG with SEMS (24) | PTBD with SEMS (32) | NR PTBD 12.6 ± 6.18 |
EUS-HG 66.5 (40–83) PTBD 68.4 (52–82) |
EUS-HG NR PTBD 24 (75%) |
Decrease in bilirubin level to less than 50% of baseline within 7 days, or less than 75% within 30 days. |
Abbreviations: EUS-CD, EUS-choledochoduodenostomy; EUS-HG, EUS-hepaticogastrostomy; NR, not reported; PTBD, percutaneous trans-hepatic biliary drainage. * This study included two subgroups of EUS-guided biliary drainage, namely EUS-CD and EUS-HG. Demographical data refer to the overall cohort.